Omnicell, Inc. (OMCL) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Omnicell, Inc. is a leading healthcare technology provider focused on medication management solutions, including automated dispensing systems, software, and consumables. The company operates as a single reportable segment, serving primarily the U.S. healthcare market (90% of revenue).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $312.2 million | $290.6 million | $622.1 million | $560.2 million |
| Gross Profit | $152.9 million | $127.7 million | $293.3 million | $238.6 million |
| Gross Margin | 49% | 44% | 47% | 43% |
| Net Income | $24.3 million | $5.6 million | $35.6 million | ($1.4 million) Loss |
| Diluted EPS | $0.52 | $0.12 | $0.77 | ($0.03) |
| Operating Cash Flow (YTD) | $122.8 million (vs. $68.7 million YTD 2025) | |||
| Cash & Equivalents | $292.2 million (as of June 30, 2026) | |||
| Debt | $168.2 million (Convertible Senior Notes, net); $0 Revolver outstanding |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 7% QoQ and 11% YTD, driven by growth in automated dispensing systems, XTExtend offerings, and SaaS/Expert Services.
- Margin Expansion: Gross margin improved significantly (49% vs. 44% in Q2 2025). This was primarily due to a $14.5 million refund received in Q2 2026 for previously paid IEEPA tariffs, recorded as a reduction to cost of product revenues.
- Profitability: The company returned to profitability, reporting net income of $24.3 million in Q2 2026 compared to $5.6 million in Q2 2025. YTD 2026 net income was $35.6 million versus a net loss of $1.4 million in YTD 2025.
- Operating Expenses: SG&A expenses increased slightly ($2.2 million) due to higher employee-related costs and restructuring charges, partially offset by a decrease in the allowance for credit losses.
- Debt Structure: The 0.25% Convertible Senior Notes due 2025 matured in September 2025. The company currently holds 1.00% Convertible Senior Notes due 2029 with a principal of $172.5 million.
Outlook, Risks, and Commentary
- Tariff Environment: The company received $14.5 million in IEEPA tariff refunds in Q2 2026. While new Section 122 tariffs expired in July 2026 and were replaced by Section 301 tariffs (10-12.5%), management does not currently expect these to have a material impact, though they remain monitoring trade policy changes.
- Market Dynamics: Management cites acute workforce shortages in healthcare (88% of hospitals report technician deficits) and rising drug diversion liabilities as drivers for demand in automation and compliance solutions.
- Liquidity: The company maintains a strong liquidity position with $292.2 million in cash and a $350 million revolving credit facility with no outstanding balance. Working capital increased to $287.9 million.
- Risks: Key risks include supply chain disruptions, semiconductor shortages, geopolitical instability, changes in the 340B Drug Pricing Program, and the potential impact of the "One Big Beautiful Bill Act" (OBBBA) on Medicaid spending.
Investor Verification Checklist
- Tariff Refund Sustainability: Verify the one-time nature of the $14.5 million IEEPA tariff refund and its impact on normalized gross margins.
- Recurring Revenue Growth: Monitor Annual Recurring Revenue (ARR) trends, specifically in SaaS and Expert Services, to gauge long-term stability.
- Convertible Note Conversion: Assess the likelihood of the 2029 Convertible Notes being converted based on stock price performance relative to the $57.25 conversion price.
- Customer Concentration: Confirm that no single customer exceeds 10% of revenue, as stated in the filing, to ensure diversification.
- Capital Expenditures: Review the $21.4 million in YTD capital expenditures for property and equipment to ensure alignment with growth strategy.